[
  {
    "ts": "2026-01-28T08:05:19+00:00",
    "headline": "Eli Lilly (LLY) Drives Q4 Gains as Pharma Fundamentals Shine Amid Sector Rotation",
    "summary": "Polen Capital Management Llc released its “Polen Focus Growth Strategy” Q4 2025 investor letter. A copy of the letter can be downloaded here. In Q4 2025, the Polen Focus Growth strategy delivered a -1.37% gross return, underperforming the Russell 1000 Growth Index (+1.12%) and the S&P 500 (+2.66%), as concentrated mega‑cap leadership and AI valuation […]",
    "url": "https://finance.yahoo.com/news/eli-lilly-lly-drives-q4-080519997.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "f05cc752-0116-35e1-a12f-dac8d7f86a34",
      "content": {
        "id": "f05cc752-0116-35e1-a12f-dac8d7f86a34",
        "contentType": "STORY",
        "title": "Eli Lilly (LLY) Drives Q4 Gains as Pharma Fundamentals Shine Amid Sector Rotation",
        "description": "",
        "summary": "Polen Capital Management Llc released its “Polen Focus Growth Strategy” Q4 2025 investor letter. A copy of the letter can be downloaded here. In Q4 2025, the Polen Focus Growth strategy delivered a -1.37% gross return, underperforming the Russell 1000 Growth Index (+1.12%) and the S&P 500 (+2.66%), as concentrated mega‑cap leadership and AI valuation […]",
        "pubDate": "2026-01-28T08:05:19Z",
        "displayTime": "2026-01-28T08:05:19Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/bb9eeca959da429f530467dc58c79488",
          "originalWidth": 768,
          "originalHeight": 512,
          "caption": "Eli Lilly (LLY) Drives Q4 Gains as Pharma Fundamentals Shine Amid Sector Rotation",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/L6CMpFrYeopyfVnnz0zZAA--~B/aD01MTI7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/bb9eeca959da429f530467dc58c79488.cf.webp",
              "width": 768,
              "height": 512,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vVDSbH1T4crsVM0rpSIWSg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/bb9eeca959da429f530467dc58c79488.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-drives-q4-080519997.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-drives-q4-080519997.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-28T11:06:53+00:00",
    "headline": "Exclusive-Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows",
    "summary": "Jan 28 (Reuters) - Novo Nordisk spent nearly $500 million on U. advertising for its GLP-1 drugs Wegovy and Ozempic in the first nine months of 2025, more than double what Eli Lilly shelled out for its ​rival medicines, as the Danish drugmaker fought for market share, data seen by Reuters shows.",
    "url": "https://finance.yahoo.com/news/exclusive-novos-wegovy-ozempic-us-110653009.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "182cce54-e0bf-3278-9a11-aae0e4384c80",
      "content": {
        "id": "182cce54-e0bf-3278-9a11-aae0e4384c80",
        "contentType": "STORY",
        "title": "Exclusive-Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows",
        "description": "",
        "summary": "Jan 28 (Reuters) - Novo Nordisk spent nearly $500 million on U. advertising for its GLP-1 drugs Wegovy and Ozempic in the first nine months of 2025, more than double what Eli Lilly shelled out for its ​rival medicines, as the Danish drugmaker fought for market share, data seen by Reuters shows.",
        "pubDate": "2026-01-28T11:06:53Z",
        "displayTime": "2026-01-28T11:06:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/52057ecfde4fda762bc487353a0bae0c",
          "originalWidth": 800,
          "originalHeight": 533,
          "caption": "FILE PHOTO: Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. REUTERS/Hollie Adams/File Photo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Y8.BnBtGUxBECcC9nPAbmg--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/52057ecfde4fda762bc487353a0bae0c.cf.webp",
              "width": 800,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VSVI8paIUF0YaI3N8PMZkg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/52057ecfde4fda762bc487353a0bae0c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/exclusive-novos-wegovy-ozempic-us-110653009.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/exclusive-novos-wegovy-ozempic-us-110653009.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]